ArticleBMC chemistry2026
Acemetacin-loaded bilosomal gel formulations prepared using different polymers for topical application: Box-Behnken design for bilosomes formulation optimization and in vitro evaluation of the formulations.
Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acemetacin (ACIN) is a poorly water-soluble nonsteroidal anti-inflammatory drug, which limits its effectiveness in topical therapeutic applications. This study aimed to enhance the delivery potential and dermal applicability of ACIN through the development of bilosome-loaded hydrogel formulations. Bilosomes were prepared using the thin-film hydration method and optimized using Box-Behnken Design (BBD). The amount of phosphotidylcholine (lecithin), cholesterol and sodium taurocholate were chosen as the formulation parameters and their effects were evaluated on the resulting vesicle size, zeta potential and entrapemnet efficiency percentage (EE%). The optimized formulation displayed a vesicle size of 137.3 nm, a zeta potential of -30.1 mV, a polydispersity index (PDI) of 0.384 and EE% of 84.5%. Bilosomes were incorporated into hydrogel bases containing hydroxypropyl methylcellulose (HPMC) or Carbopol. HPMC-based gels exhibited a favorable pH (~4) for skin application and were selected for further evaluation. These gels provided sustained drug release for up to eight hours. Cytocompatibility testing on L929 fibroblasts using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay demonstrated cell viability above 90% within the tested concentration range (0.05-2 µg/mL), indicating good biocompatibility. The bilosome-loaded HPMC gel formulation exhibited desirable physicochemical properties, sustained drug release, and excellent cytocompatibility, making it a promising vehicle for topical delivery of ACIN. Further anti-inflammatory and in vivo studies are recommended to confirm its potential for topical or anti-inflammatory applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.